Wilbur Ross Joins 28 Capital to Shape the Future of Life Sciences Investment
On April 28, 2025, 28 Capital announced a significant addition to its team with the engagement of Wilbur Ross as a Special Advisor and investor. Known for his influential role in both the public and private sectors, Ross brings a wealth of experience that aligns perfectly with 28 Capital's mission to innovate within the life sciences sector.
28 Capital, a venture capital firm rooted in life sciences, is co-led by John Boyce and Audrey Warner, emerging from its previous incarnation as Tiger Gene. The firm is focused on fostering growth through its partnerships with academic institutions and world-renowned scientists to create pioneering healthcare solutions. Wilbur Ross, who served as Secretary of Commerce during the first Trump administration, has a remarkable background that includes restructuring over $400 billion in assets, earning him titles such as the "King of Bankruptcy" by Fortune Magazine. His strategic insights into corporate finance have positioned him as a key figure in reviving economic sectors globally, earning accolades from both the Emperor of Japan and the President of South Korea.
Ross’s illustrious career also includes leadership roles with multiple corporate boards, advisory positions in academic institutions, and a rich history of philanthropic contributions, including his tenure as Chairman of the Japan Society and the Smithsonian National Board. His recent publication, Risks and Returns, has gained prominence and has been featured on several bestseller lists. Ross holds an MBA with Distinction from Harvard and a BA from Yale, adding an academic edge to his pragmatic business approach.
In comments regarding his new role, Ross expressed enthusiasm for 28 Capital’s unique model of merging scientific rigor with strategic company formation. He highlighted the firm's commitment to developing a diverse range of biotech solutions—pointing out that 28 Capital not only provides immediate investment avenues but also paves the way for future ventures that can tackle significant medical needs. He believes that the firm’s solid foundation and innovative approach make it a leader in the biotechnology space, ready to create meaningful changes in health outcomes.
Moreover, Ross’s collaboration with experts such as Dr. Larry Norton, a pivotal figure in oncology, further enhances the firm's capabilities. Dr. Norton, a prominent leader at Memorial Sloan Kettering Cancer Center, has been instrumental in bringing groundbreaking pharmaceuticals to market, and his partnership with Ross epitomizes 28 Capital's commitment to excellence in therapeutic development.
With the convergence of Ross's experience and 28 Capital's robust investment strategy—focusing on early-stage biotech firms that address significant unmet medical needs—the firm is poised for continued success. The leadership duo of Boyce and Warner, with Ross's addition, is anticipated to explore new frontiers in biomedical innovation, ultimately working towards transformative breakthroughs that could reshape the future of medicine.
28 Capital represents a new breed of venture firms that not only seek financial returns but also aim to influence positively the health landscape. Ross's Vision as part of this dynamic team strongly suggests a future where critical healthcare challenges are approached with fresh perspectives and strategic insights. His investment in 28 Capital marks not just a professional milestone, but also a hopeful step toward advancements that could benefit patients worldwide.
28 Capital, a venture capital firm rooted in life sciences, is co-led by John Boyce and Audrey Warner, emerging from its previous incarnation as Tiger Gene. The firm is focused on fostering growth through its partnerships with academic institutions and world-renowned scientists to create pioneering healthcare solutions. Wilbur Ross, who served as Secretary of Commerce during the first Trump administration, has a remarkable background that includes restructuring over $400 billion in assets, earning him titles such as the "King of Bankruptcy" by Fortune Magazine. His strategic insights into corporate finance have positioned him as a key figure in reviving economic sectors globally, earning accolades from both the Emperor of Japan and the President of South Korea.
Ross’s illustrious career also includes leadership roles with multiple corporate boards, advisory positions in academic institutions, and a rich history of philanthropic contributions, including his tenure as Chairman of the Japan Society and the Smithsonian National Board. His recent publication, Risks and Returns, has gained prominence and has been featured on several bestseller lists. Ross holds an MBA with Distinction from Harvard and a BA from Yale, adding an academic edge to his pragmatic business approach.
In comments regarding his new role, Ross expressed enthusiasm for 28 Capital’s unique model of merging scientific rigor with strategic company formation. He highlighted the firm's commitment to developing a diverse range of biotech solutions—pointing out that 28 Capital not only provides immediate investment avenues but also paves the way for future ventures that can tackle significant medical needs. He believes that the firm’s solid foundation and innovative approach make it a leader in the biotechnology space, ready to create meaningful changes in health outcomes.
Moreover, Ross’s collaboration with experts such as Dr. Larry Norton, a pivotal figure in oncology, further enhances the firm's capabilities. Dr. Norton, a prominent leader at Memorial Sloan Kettering Cancer Center, has been instrumental in bringing groundbreaking pharmaceuticals to market, and his partnership with Ross epitomizes 28 Capital's commitment to excellence in therapeutic development.
With the convergence of Ross's experience and 28 Capital's robust investment strategy—focusing on early-stage biotech firms that address significant unmet medical needs—the firm is poised for continued success. The leadership duo of Boyce and Warner, with Ross's addition, is anticipated to explore new frontiers in biomedical innovation, ultimately working towards transformative breakthroughs that could reshape the future of medicine.
28 Capital represents a new breed of venture firms that not only seek financial returns but also aim to influence positively the health landscape. Ross's Vision as part of this dynamic team strongly suggests a future where critical healthcare challenges are approached with fresh perspectives and strategic insights. His investment in 28 Capital marks not just a professional milestone, but also a hopeful step toward advancements that could benefit patients worldwide.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.